Showing results (1-10 of 106) with videos related to
Sort By:
Pageof 11
Nature Reviews. Drug Discovery|March 1, 2014
Targeting tumour-supportive cellular machineries in anticancer drug developmentMatthias Dobbelstein, Ute MollCell Cycle (Georgetown, Tex.)|February 5, 2011
While p73 is essential, p63 is completely dispensable for the development of the central nervous systemLena Holembowski, Ramona Schulz, Flaminia Talos, et al.Journal of Virology|June 29, 2004
E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infectionUrs Hobom, Matthias DobbelsteinCancer Research|November 3, 2006
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapyDominique Kranz, Matthias DobbelsteinCell Cycle (Georgetown, Tex.)|May 12, 2011
Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exonUlrike Beyer, Matthias DobbelsteinCell Cycle (Georgetown, Tex.)|January 26, 2006
Activating Ras mutations fail to ensure efficient replication of adenovirus mutants lacking VA-RNAMichael Schümann, Matthias DobbelsteinCancer Research|February 3, 2006
Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progenyMichael Schümann, Matthias DobbelsteinCell Cycle (Georgetown, Tex.)|July 16, 2004
p73 and p63: why do we still need them?Giovanni Blandino, Matthias DobbelsteinThe Journal of General Virology|November 24, 1999
Failure of viral oncoproteins to target the p53-homologue p51AJudith Roth, Matthias DobbelsteinPageof 11